Overview
Short Course: October 21
Conference: October 27-29
Digital technology is transforming the drug development process. The rise of wearable and mobile technologies along with cloud technology, Artificial Intelligence and related platforms, now enable the collection of frequent, specific, and multidimensional data throughout the length of trials. These technologies have the potential to enable innovative trial designs, improve the patient experience, act as recruitment and retention tools, and establish novel end points in clinical studies.
With these technologies, large amounts of data are collected. How to best address evaluating fit-for-purpose, standardization, ethical concerns, and regulatory approaches, are key issues to address in the digital era.
DIA’s Digital Technology in Clinical Trials Conference will bring together thought leaders from regulatory agencies, biotech, pharma, patients, and academia to discuss the latest advances, challenges, and forward-thinking approaches for implementing digital technology to improve clinical trials. While the conference will focus on the impact of digitalization in clinical trials today, we will make time to explore future applications and how they may enable the clinical trials of tomorrow.
Co-Sponsored with Critical Path Institute’s ePRO Consortium
Featured
Want to learn more about Digital Technology in Clinical Trials? You've come to the right site!
Program Committee
-
Sonya Eremenco, MA Executive Director, PRO Consortium
Critical Path Institute, United States -
Jennifer Goldsack, MA, MBA, MS Chief Executive Officer
Digital Medicine Society (DiMe), United States -
Erin Iturriaga, MSN Clinical Trials Specialist
National Heart, Lung, and Blood Institute (NHLBI), United States -
Jonathan Andrus, MS Past Chair/Current Treasurer
Society For Clinical Data Management, United States -
Lindsay Stiles Kehoe, MS Senior Project Manager
Clinical Trials Transformation Initiative (CTTI), United States -
Bill Byrom, PhD Vice President, Product Intelligence and Positioning; Principal, eCOA Science
Signant Health , United Kingdom -
Megan Doyle, JD, MPH Associate Vice President, Assistant General Counsel - Diagnostics
Eli Lilly & Company, United States -
Estelle Haenel, DrSc, PharmD Medical Director
Kayentis, France -
Jules Mitchel, PhD, MBA President and CEO
THI Pharma Services, United States -
Paul O'Donohoe, MS, MSc Senior Director, eCOA Product and Science
Medidata Solutions, United States -
Lauren Oliva, PharmD, RPh US Lead, Global Regulatory Policy
Biogen, United States -
Keith Wenzel Volunteer
DIA Study Endpoints Community, United States -
Anindita Saha Associate Director Strategic Initiatives, Digital Health Center of Excellence
FDA, United States -
Prem Sreenivasan, PhD Director
HITLAB, United States
Have an account?